🔎 Trials Near Me

Beranda › Leiomyosarcoma › Texas

Uji klinis Leiomyosarcoma di Texas

7 studi untuk Leiomyosarcoma mencari peserta di lokasi di Texas.

Kota di Texas

Teks studi resmi (Bahasa Inggris)

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

  • UT MD Anderson Cancer Center, Houston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06498648

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • M D Anderson Cancer Center, Houston
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT04031677

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

  • UT MD Anderson Cancer Center, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT05711615

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

  • MD Anderson Cancer Center, Houston
  • NEXT Houston, Houston
  • NEXT Dallas, Irving
  • dan 2 lainnya
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT06975293

A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy

  • MD Anderson Cancer Center, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT07633756

Metastatic Leiomyosarcoma Biomarker Protocol

  • MD Anderson, Houston
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 24 Jun 2026 · NCT05653388

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

  • MD Anderson Cancer Center, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Jun 2026 · NCT06789172

Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.